Risk of death following COVID-19 vaccination or positive SARS-CoV-2 test in young people in England

[1]  Colin Simpson,et al.  Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland , 2022, Nature Communications.

[2]  L. Hartling,et al.  Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review , 2022, BMJ.

[3]  M. Gulliford,et al.  Cardiometabolic outcomes up to 12 months after COVID-19 infection. A matched cohort study in the UK , 2022, PLoS medicine.

[4]  S. Brunak,et al.  Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors , 2022, Nature Communications.

[5]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[6]  Paul J. Birrell,et al.  Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines , 2022, Nature Medicine.

[7]  M. Bertrand,et al.  A modified self‐controlled case series method for event‐dependent exposures and high event‐related mortality, with application to COVID‐19 vaccine safety , 2022, Statistics in medicine.

[8]  Michael John Smith,et al.  Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. , 2022, JAMA.

[9]  K. Khunti,et al.  Risk of myocarditis following sequential COVID-19 vaccinations by age and sex , 2021, medRxiv.

[10]  H. Sørensen,et al.  SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study , 2021, BMJ.

[11]  R. Viner,et al.  Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year , 2021, Nature Medicine.

[12]  K. Khunti,et al.  Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection , 2021, Nature Medicine.

[13]  A. Gundlapalli,et al.  Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data — United States, March 2020–January 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[14]  P. Farrington,et al.  Avoiding bias in self‐controlled case series studies of coronavirus disease 2019 , 2021, Statistics in medicine.

[15]  K. Khunti,et al.  Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study , 2021, BMJ.

[16]  P. Farrington,et al.  Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study , 2021, The Lancet.

[17]  C. Robertson,et al.  Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study , 2021, BMJ.

[18]  D. Swerdlow,et al.  Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data , 2021, The Lancet.

[19]  David A. Drew,et al.  Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study , 2021, The Lancet Infectious Diseases.

[20]  Heather J. Whitaker,et al.  Self-controlled case series studies : a modelling guide with R , 2018 .

[21]  Irene Petersen,et al.  Self controlled case series methods: an alternative to standard epidemiological study designs , 2016, British Medical Journal.

[22]  O. Wichmann,et al.  Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: a systematic review , 2015, BMC Infectious Diseases.

[23]  K. Wilson,et al.  Drug safety studies and measures of effect using the self‐controlled case series design , 2013, Pharmacoepidemiology and drug safety.

[24]  Heather J Whitaker,et al.  Case series analysis for censored, perturbed, or curtailed post-event exposures. , 2008, Biostatistics.

[25]  Patrick Musonda,et al.  Tutorial in biostatistics: the self‐controlled case series method , 2006, Statistics in medicine.